BGB-3111-210

Completed

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström’s Macroglobulinemia (WM)

Beigene Study ID info

BGB-3111-210

ClinicalTrials.gov ID info

China Drug Trials ID info

CTR20170208

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan